MPI
ALNY icon

Mairs & Power Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mairs & Power Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,300
Closed -$217K – 188
2015
Q4 		$217K Buy
+2,300
New +$213K ﹤0.01% 181
2015
Q3 		– Sell
-2,200
Closed -$264K – 175
2015
Q2 		$264K Hold
2,200
– – ﹤0.01% 160
2015
Q1 		$230K Hold
2,200
– – ﹤0.01% 173
2014
Q4 		$213K Buy
+2,200
New +$204K ﹤0.01% 186

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Mairs & Power Inc's ALNY Position: Q1 2016 in Review

Mairs & Power Inc sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2016, closing a stake of 2,300 shares — an estimated $217K sold.

Mairs & Power Inc first reported a position in ALNY in Q4 2014 and held it in 4 quarters. The position peaked at $264K in Q2 2015. 255 funds tracked by Wall St. Rank hold ALNY as of Q1 2016.

  • Mairs & Power Inc reported no remaining Alnylam Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Mairs & Power Inc sold 2,300 Alnylam Pharmaceuticals shares in Q1 2016, an estimated $217K.
  • Mairs & Power Inc first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • Mairs & Power Inc's Alnylam Pharmaceuticals position peaked at $264K in Q2 2015.
  • 255 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2016.

Based on Mairs & Power Inc's 13F filing for Q1 2016, filed 16 May 2016.